Prologue Medicines names Stephen Harrison chief scientific officer
Prologue Medicines appointed Stephen Harrison as chief scientific officer on October 13, the company announced in a press release. Harrison will direct its scientific and research strategy, including work on the DELVE machine learning platform and its pipeline of medicines derived from viral proteins.
Harrison previously served as chief scientific officer at Nucleome Therapeutics and held leadership roles at Engine Biosciences, Relypsa and KAI Pharmaceuticals. His work included contributions to the approved medicines Veltassa and Parsabiv.
Prologue also appointed Jason Silvers and Adrian Rawcliffe to its board of directors. Silvers is president and chief financial officer of Generate Biomedicines, while Rawcliffe is a CEO Partner at Flagship Pioneering and chief executive of Etiome.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Oct 13 HealthpointCapital Invests in Surgical Software Company Ospitek Oct 13 symplr Survey Finds Nearly Half of Hospital Operations Remain Manual Oct 13 MediRoutes Launches Predictive ETAs for Medical Transport Oct 13 Medsender Launches Agentic Referral Management for Specialty Practices Oct 13 Sensydia Raises More Than $6 Million for AI Cardiac SystemLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Sequential Plans London Conference on AI Ingredient Discovery
NAVER D2SF Backs ImpriMed in $10 Million Bridge Round
Basecamp Research Raises $140 Million for AI Designed Therapeutics
Novo Nordisk Partners With Anthropic on Drug Research
Cellular Intelligence Adds Yann LeCun and Three Scientists to Advisory Board
Daily AI Brief: the AI news that matters, in your inbox.